Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344351
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2024-03-28
Brief Title:
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Phase I Study to Evaluate the Safety Tolerance and Pharmacokinetics of TQB3006 Tablets in Patients With Advanced Malignant Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study includes two stage dose escalation and dose extension with a single dose and a multiple dose study This is a single-center open non-randomized single arm study to evaluate the safety tolerability and pharmacokinetics of TQB3006 tables in patients with advanced malignant cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None